Lair Centre

Vancouver, British Columbia V5Z 1HZ

0 studies enrolling now · 8 studies all time

What they study most

Chronic Hepatitis C, Hepatitis B, Chronic, Hepatitis C, Chronic, Non-Alcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Studies at this site

• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis — Stopped early
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients — Completed
• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay — Completed
• GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype — Stopped early